PMID- 16425128
OWN - NLM
STAT- MEDLINE
DCOM- 20060525
LR  - 20190508
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 193
IP  - 4
DP  - 2006 Feb 15
TI  - Abnormal presence of semimature dendritic cells that induce regulatory T cells in 
      HIV-infected subjects.
PG  - 494-504
AB  - Dendritic cells (DCs), because they orchestrate the immune response to microbes, 
      represent an ideal target for pathogens attempting to evade the immune system. We 
      hypothesized that interactions between human immunodeficiency virus (HIV) and DCs 
      lead to the development of a semimature state, in which DCs migrate to lymph 
      nodes but induce tolerance in T cells, rather than immunity. We found that lymph 
      nodes from untreated HIV-infected subjects contained an abundance of semimature 
      DCs, the disappearance of which correlated with the initiation of highly active 
      antiretroviral therapy (HAART). Such lymph nodes also contained an abundance of T 
      cells that had a regulatory phenotype and that persisted after HAART. Lymph node 
      DCs from untreated HIV-infected subjects cultured with normal allogeneic T cells 
      induced these T cells to adopt the phenotype of regulatory T cells, an ability 
      that was lost after HAART. We conclude that HIV infection correlates with the 
      presence of semimature DCs that stimulate T cell tolerance rather than immunity. 
      These regulatory T cells may contribute to the lack of effective HIV immune 
      responses.
FAU - Krathwohl, Mitchell D
AU  - Krathwohl MD
AD  - Department of Medicine, University of Minnesota, Minneapolis, USA. 
      mitch@rosettastonelabs.com.
FAU - Schacker, Timothy W
AU  - Schacker TW
FAU - Anderson, Jodi L
AU  - Anderson JL
LA  - eng
GR  - AI-01544/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20060119
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Anti-HIV Agents/*therapeutic use
MH  - Antiretroviral Therapy, Highly Active
MH  - CD4-Positive T-Lymphocytes/immunology/pathology/virology
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology/metabolism/pathology
MH  - HIV Infections/drug therapy/*immunology
MH  - HIV-1/*physiology
MH  - Humans
MH  - Leukocytes, Mononuclear/virology
MH  - Lymph Nodes/pathology/virology
MH  - T-Lymphocytes, Regulatory/*immunology
EDAT- 2006/01/21 09:00
MHDA- 2006/05/26 09:00
CRDT- 2006/01/21 09:00
PHST- 2005/03/08 00:00 [received]
PHST- 2005/09/01 00:00 [accepted]
PHST- 2006/01/21 09:00 [pubmed]
PHST- 2006/05/26 09:00 [medline]
PHST- 2006/01/21 09:00 [entrez]
AID - JID34575 [pii]
AID - 10.1086/499597 [doi]
PST - ppublish
SO  - J Infect Dis. 2006 Feb 15;193(4):494-504. doi: 10.1086/499597. Epub 2006 Jan 19.